Last $2.61 USD
Change Today -0.08 / -2.97%
Volume 2.5M
VVUS On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

vivus inc (VVUS) Snapshot

Open
$2.67
Previous Close
$2.69
Day High
$2.68
Day Low
$2.54
52 Week High
03/6/14 - $6.40
52 Week Low
02/4/15 - $2.41
Market Cap
271.1M
Average Volume 10 Days
2.0M
EPS TTM
$-0.78
Shares Outstanding
103.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VIVUS INC (VVUS)

vivus inc (VVUS) Related Businessweek News

View More BusinessWeek News

vivus inc (VVUS) Details

VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health in the United States and the European Union. The company offers Qsymia, a drug for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also developing Qsymia, which has completed Phase II clinical studies for the treatment of obstructive sleep apnea and diabetes. The company has an agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. VIVUS, Inc. was founded in 1991 and is headquartered in Mountain View, California.

vivus inc (VVUS) Top Compensated Officers

Chief Executive Officer, Chief Commercial Off...
Total Annual Compensation: $212.1K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $274.8K
Senior Vice President of Business Development...
Total Annual Compensation: $398.8K
Vice President of Clinical Development
Total Annual Compensation: $419.7K
Vice President of U S Operations and General ...
Total Annual Compensation: $369.9K
Compensation as of Fiscal Year 2013.

vivus inc (VVUS) Key Developments

VIVUS Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

VIVUS Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported total revenue of $21,732,000 compared to $44,057,000 a year ago. Loss from operations was $17,385,000 compared to $8,695,000 a year ago. Loss from continuing operations before income taxes was $25,416,000 compared to $17,113,000 a year ago. Loss from continuing operations was $25,447,000 compared to $17,164,000 a year ago. Net loss was $25,447,000 compared to $17,164,000 a year ago. Basic and diluted net loss per share from continuing operations was $0.25 compared to $0.17 a year ago. For the full year, the company reported total revenue of $114,181,000 compared to $81,082,000 a year ago. Loss from operations was $50,711,000 compared to $154,614,000 a year ago. Loss from continuing operations before income taxes was $83,276,000 compared to $174,849,000 a year ago. Loss from continuing operations was $82,647,000 compared to $174,946,000 a year ago. Net loss was $82,647,000 compared to $174,456,000 a year ago. Basic and diluted net loss per share from continuing operations was $0.80 compared to $1.72 a year ago.

VIVUS Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 03:35 PM

VIVUS Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 03:35 PM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: Seth H. Z. Fischer, Chief Executive Officer, Chief Commercial Officer and Director.

VIVUS Inc. to Report Q4, 2014 Results on Feb 24, 2015

VIVUS Inc. announced that they will report Q4, 2014 results at 4:30 PM, US Eastern Standard Time on Feb 24, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VVUS:US $2.61 USD -0.08

VVUS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arena Pharmaceuticals Inc $4.51 USD -0.24
GlaxoSmithKline Consumer Healthcare Ltd 5,802 INR +18.30
GlaxoSmithKline PLC 1,542 GBp -12.50
Roche Holding AG SFr.258.80 CHF -0.20
View Industry Companies
 

Industry Analysis

VVUS

Industry Average

Valuation VVUS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.4x
Price/Book 3.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VIVUS INC, please visit www.vivus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.